Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

Once-daily oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss observed with semaglutide, the active ingredient in Ozempic and Wegovy. The preclinical result supports ART27.13's potential in obesity treatment, though human clinical efficacy and safety remain unproven.